VANCOUVER, British Columbia, May 9, 2018 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (OTC: MYMMF) (the"Company" or "MYM") is pleased to provide the following update regarding the Sublime Culture Inc. ACMPR production facility located in Laval, Quebec.
The Sublime Culture Inc. Laval
"The Company is satisfied that Sublime Culture Inc. has provided Health Canada with all the necessary information in order for them to move ahead with the license application," said Rob Gietl, CEO of MYM. "The completed Laval facility is currently 10,000 square feet. Phase two of the project will see the growing capacity increased to 37,000 square feet by the end of 2018. We have been advised by Health Canada that our application is in the final review stage. We are looking forward to beginning production at the facility and building value for our shareholders, the City of Laval, and Province of Quebec."
MYM has retained the services of Cannabis Compliance Inc. to consult the Company on regulatory compliance and due diligence for all its ACMPR projects in Canada.
About Cannabis Compliance Inc.
Cannabis Compliance Inc. (CCI) offers risk mitigation, due diligence and regulatory compliance for commercial cannabis producers and resellers around the world. They focus on the Global market and provide their clients with trusted and comprehensive solutions. CCI has extensive expertise in regulatory compliance, cultivation/horticulture, security designs/tender, facility designs/build-outs, quality assurance, training programs, auditing, Good Production Practices (GPP), Good Manufacturing Practices (GMP), Good Agricultural and Collection Practices (GACP), Import & Export, staff recruitment and financial planning. CCI exists to empower the future leaders in the global cannabis industry.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).
ON BEHALF OF THE BOARDRob Gietl, CEO MYM Nutraceuticals Inc. www.mymarijuana.ca
Keep up to date with MYM on our social media channels:
Twitter: @MYM_NutraFacebook: @mymcanadaInstagram: @MYM_Nutra
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
Investor RelationsTerry Brownfirstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/mym-corporate-update-sublime-culture-inc-acmpr-cultivation-license-under-final-review-with-health-canada-300645178.html
SOURCE MYM Nutraceuticals Inc.
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All